| Document |
Document Title |
|
WO/2015/171753A1 |
Described herein are methods for treating preterm labor, stopping labor prior to Cesarean delivery, preventing preterm labor, or controlling the timing of parturition by administering a chemical compound, such as a muscarinic receptor an...
|
|
WO/2015/169173A1 |
The present invention provides methods and compositions for treating cancer, reducing side effects, and reducing postmenopausal symptoms comprising anordrin or analog thereof (such as anordrin) alone or in combination with at least one o...
|
|
WO/2015/172102A1 |
This invention relates to treating female sexual arousal disorder and/or improving female sexual response, and related symptoms, preferably with topical prostaglandin compositions.
|
|
WO/2015/163037A1 |
The present invention addresses the problem of providing an egg drop syndrome (EDS) vaccine that is capable of effectively preventing EDS and can be stably supplied. To solve this problem, provided is an EDS vaccine that comprises as an ...
|
|
WO/2015/161766A1 |
The present invention relates to a choline salt of a selenium-containing compound, and preparation method and use thereof. The structure of the selenium-containing compound choline salt of the present invention is as represented by formu...
|
|
WO/2015/163604A1 |
The present invention relates to a novel selective androgen receptor agonist, a preparing method thereof, and a pharmaceutical composition containing a pharmaceutically effective amount thereof. The selective androgen receptor agonists o...
|
|
WO/2015/162452A1 |
The present invention relates to compounds of formula 1, or isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, S-oxides or N-oxides thereof, and processes for their preparation. T...
|
|
WO/2015/159103A1 |
Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are de...
|
|
WO/2015/160284A1 |
The group of inventions relates to pharmaceutical compositions and techniques for producing same from animal-derived raw materials, and can be used for the treatment and rehabilitation of various types of endometriosis and certain onc...
|
|
WO/2015/160262A1 |
O. no. P61401155PCT00 The present invention relates to a composition comprising fertilized shell egg, shark cartilage, pea protein extract, coenzyme Q10, vitamin K2, fish oil and optionally borage oil; and use of said composition for del...
|
|
WO/2015/158107A1 |
Disclosed are a drug for clearing "heat" to reduce the "fire" consisting of 1 part of borneol and 20-30 parts of tung oil, and preparation method and use thereof.
|
|
WO/2015/159922A1 |
Provided is a method for producing a carrot extract which contains Rg3 at a high concentration, undergoes discoloration to a reduced extent and has excellent color stability. A method for producing a carrot extract, said method comprisin...
|
|
WO/2015/158006A1 |
The present invention provides the use of the gene or protein of adenylate kinase 6 (AK6) or the combination of AK6 and other 14 genes or proteins related to male fertility for (i) preparing the agent or kit for detecting male infertilit...
|
|
WO/2015/158823A1 |
The invention concerns a veterinary pharmaceutical composition comprising at least one active veterinary pharmaceutical substance selected from gonadorelin and gonadorelin analogues and salts of gonadorelin and gonadorelin analogues. A f...
|
|
WO/2015/158875A1 |
The present invention pertains to methods for controlled ovarian hyperstimulation in a female subject using improved recombinant human follicle-stimulating hormone (rhFSH). The methods result in a high number of fertilizable oocytes even...
|
|
WO/2015/155566A1 |
The present invention relates to compounds of formula I, or isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, S-oxides or N- oxides thereof, and processes for their preparation. ...
|
|
WO/2015/152409A1 |
In order to provide a novel cancer treatment method using an FTD/TPI combination drug that exhibits an outstanding anti-tumor effect and has few side effects, the present invention provides an anti-tumor drug that is characterized in tha...
|
|
WO/2015/151091A1 |
A method of treating or preventing gonadal or uterine toxicity induced by an agent in a subject is provided. Accordingly there is provided a method comprising administering to a subject a therapeutically effective amount of pigment epith...
|
|
WO/2015/147763A1 |
The present invention which relates to herbal compound for elimination of pain women experience during their menstrual periods; is obtained in gel-like form by condensation of the vapor of minimum 100 gr of salvia which is boiled in 1 li...
|
|
WO/2015/139301A1 |
An oil mixture for nourishing yin, replenishing the kidney, and improving sexual function: as a percentage of mass, the oil mixture is composed of the following components: 40-50% soybean oil, 5-10% deer oil, 3-5% ganoderma lucidum spore...
|
|
WO/2015/137633A1 |
The present invention provides a composition containing black raspberry oil, raspberry oil and mulberry oil. The composition has effects of blood circulation improvement, climacteric symptom alleviation, immunological enhancement, atopy ...
|
|
WO/2015/135915A1 |
The invention relates to a mucoadhesive sustained-release vaginal tablet comprising at least one probiotic strain of the genus Lactobacillus compressed with an excipient suitable for conferring upon said tablet the properties of vaginal ...
|
|
WO/2015/135470A1 |
A use of isomaltulose in the preparation of a composition for a vagina, wherein the amount of isomaltulose used is 0.05-20% (w/w). A vaginal composition contains 0.05-20% (w/w) of isomaltulose. The composition may be a health product, he...
|
|
WO/2015/136096A1 |
The present invention provides a topical composition comprising extract from Coriolus versicolor for use for preventing and/or treating by vaginal or cervical administration of a vaginal or cervical disorder which is caused by an infecti...
|
|
WO/2015/138919A1 |
Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. In one embodiment, the compounds described herein mimic...
|
|
WO/2015/134695A1 |
The invention relates to a method of mitigating the side effects of a phosphodiesterase type V (PDE5) inhibitor in a subject that experiences side effects when administered a PDE5 inhibitor. The method comprises simultaneously administer...
|
|
WO/2015/129782A1 |
Provided is a selective EP2 agonist exhibiting excellent safety. A compound represented by general formula (I) (all the symbols in general formula (I) are as indicated in the description), a salt thereof, an N-oxide thereof, solvates of ...
|
|
WO/2015/129919A1 |
The present invention relates to the provision of a new pharmaceutical composition that is cancer-specific and has few side effects. The present invention provides a pharmaceutical composition including a monoclonal antibody that has hig...
|
|
WO/2015/123748A1 |
The present invention relates to novel 6,7-dihydro-3H-oxazolo[3,4-a]pyrazine-5,8-dione derivatives or to a mixture thereof. The present invention also relates to pharmaceutical compositions comprising an effective quantity of one of said...
|
|
WO/2015/121227A1 |
The invention relates to bromodomain protein-inhibiting, in particular BET protein-inhibiting, and preferably BRD4-inhibiting 6,9-disubstituted 2,3-benzodiazepines of general formula (I), in which R1a, R1b, R1c, R2, R3, R4, R5, R6a and R...
|
|
WO/2015/121268A1 |
The invention relates to bromodomain protein-inhibiting, in particular BET protein-inhibiting, and preferably BRD4-inhibiting 3H-2,3-benzodiazepines of general formula (I), in which R1a, R1b, R1c, R2, R3, R4 and R5 have the meanings spec...
|
|
WO/2015/114481A1 |
The present invention relates to a contraceptive formulation comprising a styrene-(maleic acid-maleic anhydride)n copolymer as active ingredient, and methods for preparation and use thereof.
|
|
WO/2015/114647A1 |
The present invention relates to Pyrazolopyrimidinone compounds as PDE5 inhibitors with better IC50 value, good in vivo efficacy and PK profile and a process for the preparation thereof. The present invention covers the pyrazolo pyrimidi...
|
|
WO/2015/109666A1 |
Disclosed are an ester group-containing aromatic propionamide compound, and a preparation method therefor and uses thereof, and provides a chemical structure formula of the new ester group-containing aromatic propionamide compound. The c...
|
|
WO/2015/111716A1 |
Provided are a method for elucidating a polynucleotide which is a novel gene responsible for cancer, and detecting the polynucleotide or the polypeptide coded thereby on the basis of this finding; a kit and primer set for this detection;...
|
|
WO/2015/108203A1 |
The present invention pertains to providing: a pharmaceutical composition for cancer therapy, in which a chemical therapeutic agent is conjugated to a novel monoclonal antibody that binds to SLC6A6 or the extracellular domain thereof; an...
|
|
WO/2015/106697A1 |
Provided is an immunity enhancing therapeutic vaccine comprising a gene vector based on recombinant adenovirus and three key elements: 1) an HPV antigen including the E6 and E7 multivalent fusion proteins of HPV types 16 and 18; 2) an im...
|
|
WO/2015/098857A1 |
Provided is a hydrated crystal of 4-(((6S,9S)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(qu
inolone-8-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazi
ne-6-yl)methyl)phenyl dihydrogen phosphate, said crystal having a diffraction pea...
|
|
WO/2015/098113A1 |
The present invention makes it possible to obtain a novel therapeutic drug for malignant tumors. Specifically, the present invention provides a therapeutic drug for malignant tumors, said drug including an anti-LSR (lipolysis stimulated ...
|
|
WO/2015/093534A1 |
[Problem] To provide a novel triazinone compound having inhibitory activity on T-type potential-dependent calcium channels, and which is useful for treating pain, chronic kidney disease, and atrial fibrillation in particular. [Solution] ...
|
|
WO/2015/095713A1 |
The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using en...
|
|
WO/2015/089656A1 |
Compositions comprising the antioxidants vitamin C (ascorbate), vitamin E (tocopherol), and coenzyme Q10 (ubiquinone) have been found to be useful in promoting female fertility. Such compositions may further comprise vitamin D and folic ...
|
|
WO/2015/091315A1 |
Spiroindoline-piperidine derivatives of formula (I) as gonadotropin- releasing hormone (GnRH) receptor antagonists, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of ...
|
|
WO/2015/086508A1 |
A series of substituted benzotriazole derivatives, being potent modulators of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiova...
|
|
WO/2015/083816A1 |
Provided is a new NK3 receptor selective ligand which is expected to have high activity and high selectivity, and to act in a sustained manner in vivo. A compound expressed by formula (I) X1 - A2 - A3 - X4 - X5 - Met - NH2 [the symbols...
|
|
WO/2015/084264A1 |
We describe an ELABELA polypeptide comprising a sequence CXXXRCXXXHSRVPFP (SEQ ID NO: 1), in which X signifies an amino acid residue, such as a sequence selected from the group consisting of: SEQ ID NO: 2 to SEQ ID NO: 18, preferably CLQ...
|
|
WO/2015/082374A1 |
Spiroindoline-thiopyran-imine-oxide derivatives of formula (I), process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medic...
|
|
WO/2015/078713A1 |
The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vagi...
|
|
WO/2015/076455A1 |
The present invention relates to an animal ovarian function inactivating composition using lactic acid. The present invention enables that a composition selectively injected for ovarian inactivation does not cause any impairment in growt...
|
|
WO/2015/075032A1 |
A combination of dosage units for use in the treatment of pre-term labour condition The invention refers to a combination of dosage units of a pharmaceutical or veterinary liquid composition for oral administration for use in the treatme...
|
